The Dawn of Precision Medicine in Neurodegenerative Diseases
We are on the precipice of Precision Medicine in neurodegenerative diseases (NDDs)

Special thanks to Efe Alyanak, Thomas Angiulo, Puja Ghelani, Alli Gitnik, Hayden Kickbush, Jeff Stoll, Jack Verity
We are on the precipice of precision medicine in neurodegenerative diseases (NDDs) but many key questions remain:
- What can be learned from cutting edge approaches in oncology to drive better patient outcomes in NDDs?
- Why have NDDs remained untreatable for so long and what can be done in in the future?
- Are we thinking about the causes of NDDs in the right way or do we need to take a step back?
- Is the amyloid approach the panacea for all patients?
- What will it take to diagnose the disease early?
- How does the patient journey need to evolve for a precision medicine future in NDD?
Dive into our thinking:
The precision medicine future in neurodegenerative diseases
Download PDFKey takeaways
1
2
3
4
The KPMG Precision Medicine practice is a leader in innovation across all therapeutic areas, in markets around the world. Our comprehensive offerings range from strategic front-end ideation and planning, to commercial, financial, and operational due diligence, and continuing through integration and separation. Our approach is fueled by proprietary clinical and lab data which is unparalleled in the market. Click to see more examples of the transformative work we are doing in strategy, deals and operations for all stakeholders in the Precision Medicine ecosystem.
Explore more
Meet our team


